CL2014000799A1 - Un metodo para el tratamiento de un paciente que ha sufrido un accidente cerebrovascular que comprende administrar aminopiridina o una de sus sales - Google Patents

Un metodo para el tratamiento de un paciente que ha sufrido un accidente cerebrovascular que comprende administrar aminopiridina o una de sus sales

Info

Publication number
CL2014000799A1
CL2014000799A1 CL2014000799A CL2014000799A CL2014000799A1 CL 2014000799 A1 CL2014000799 A1 CL 2014000799A1 CL 2014000799 A CL2014000799 A CL 2014000799A CL 2014000799 A CL2014000799 A CL 2014000799A CL 2014000799 A1 CL2014000799 A1 CL 2014000799A1
Authority
CL
Chile
Prior art keywords
suffered
stroke
salts
patient
treatment
Prior art date
Application number
CL2014000799A
Other languages
English (en)
Inventor
Andrew R Blight
Anthony O Caggiano
Tom J Parry
Jennifer F Iaci
Original Assignee
Acorda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acorda Therapeutics Inc filed Critical Acorda Therapeutics Inc
Publication of CL2014000799A1 publication Critical patent/CL2014000799A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
CL2014000799A 2011-10-04 2014-04-02 Un metodo para el tratamiento de un paciente que ha sufrido un accidente cerebrovascular que comprende administrar aminopiridina o una de sus sales CL2014000799A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161543150P 2011-10-04 2011-10-04
US201261591833P 2012-01-27 2012-01-27
US201261648695P 2012-05-18 2012-05-18

Publications (1)

Publication Number Publication Date
CL2014000799A1 true CL2014000799A1 (es) 2014-11-03

Family

ID=47143280

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014000799A CL2014000799A1 (es) 2011-10-04 2014-04-02 Un metodo para el tratamiento de un paciente que ha sufrido un accidente cerebrovascular que comprende administrar aminopiridina o una de sus sales

Country Status (21)

Country Link
US (2) US20130085167A1 (es)
EP (1) EP2766017B1 (es)
JP (1) JP6134722B2 (es)
KR (1) KR20140084120A (es)
CN (2) CN104220072B (es)
AR (1) AR088764A1 (es)
AU (2) AU2012318719B2 (es)
BR (1) BR112014008082A8 (es)
CA (1) CA2850635A1 (es)
CL (1) CL2014000799A1 (es)
CO (1) CO7061067A2 (es)
CR (1) CR20140153A (es)
EA (1) EA029558B1 (es)
HK (2) HK1201204A1 (es)
IL (1) IL231809B (es)
MX (1) MX354667B (es)
SG (2) SG11201401248YA (es)
TW (1) TWI592156B (es)
UA (1) UA114486C2 (es)
WO (1) WO2013052575A1 (es)
ZA (1) ZA201402432B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014172266A1 (en) * 2013-04-15 2014-10-23 Acorda Therapeutics, Inc. Methods for treating sensorimotor impairments associated with certain types of stroke using aminopyridines
US10172842B2 (en) 2015-09-11 2019-01-08 PharmaDax Inc. Sustained release oral dosage form containing dalfampridine
DE102017115701B4 (de) * 2017-07-12 2022-03-03 Lts Lohmann Therapie-Systeme Ag Fampridin-TTS
CN109172573B (zh) * 2018-09-12 2021-01-26 黑龙江中桂制药有限公司 一种口服抗血栓药物及其用途
CN115018836A (zh) * 2022-08-08 2022-09-06 四川大学 一种癫痫病灶自动分割与预测方法、***及设备

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0696575B2 (ja) * 1987-09-17 1994-11-30 三菱化成株式会社 ４−アミノピリジン誘導体及びその酸付加塩
JPH03505868A (ja) 1988-04-08 1991-12-19 マサチユセツツ・インスチチユート・オブ・テクノロジー 神経性疾患を治療するための方法及び組成物
IE82916B1 (en) 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
CA2085785C (en) * 1992-12-18 2005-03-15 Robert R. Hansebout The use of 4-aminopyridine in the treatment of a neurological condition
US5952357A (en) 1993-12-23 1999-09-14 Cornell Research Foundation, Inc. Treating diseases of the anterior horn cells
DE60034110T2 (de) * 1999-02-09 2007-12-06 The Uab Research Foundation, Birmingham Verwendung von 4-aminopyridin zur behandlung von peripheren neuropathien
FR2791571B1 (fr) * 1999-04-02 2002-10-04 Sod Conseils Rech Applic Association inhibiteur(s) de no synthase et antioxydant(s) metabolique(s)
CA2403555A1 (en) * 2000-03-28 2001-10-04 Queen's University At Kingston Methods for effecting neuroprotection
GB0119435D0 (en) * 2001-02-15 2001-10-03 Aventis Pharm Prod Inc Method of treating of demyelinating diseases or conditions
US8007826B2 (en) * 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions
EP2108145A4 (en) * 2007-01-26 2011-12-07 Safenet Inc PROTECTING CONFIDENTIAL INFORMATION IN AN INVALIDATE RECIPIENT
EP2667869A1 (en) * 2011-01-28 2013-12-04 Acorda Therapeutics, Inc. Use of potassium channel blockers to treat cerebral palsy

Also Published As

Publication number Publication date
EA029558B1 (ru) 2018-04-30
WO2013052575A1 (en) 2013-04-11
MX354667B (es) 2018-03-15
CN104220072A (zh) 2014-12-17
TWI592156B (zh) 2017-07-21
CA2850635A1 (en) 2013-04-11
AU2012318719B2 (en) 2017-10-19
UA114486C2 (uk) 2017-06-26
AU2018200114A1 (en) 2018-01-25
EP2766017A1 (en) 2014-08-20
CN104220072B (zh) 2018-04-17
CR20140153A (es) 2014-07-04
AU2012318719A1 (en) 2014-04-17
US20160067232A1 (en) 2016-03-10
KR20140084120A (ko) 2014-07-04
NZ623255A (en) 2016-08-26
CN108451953A (zh) 2018-08-28
TW201321000A (zh) 2013-06-01
AR088764A1 (es) 2014-07-02
BR112014008082A8 (pt) 2018-01-16
MX2014003997A (es) 2014-07-22
EA201490562A1 (ru) 2014-08-29
ZA201402432B (en) 2020-08-26
JP2014531470A (ja) 2014-11-27
BR112014008082A2 (pt) 2017-07-18
HK1204965A1 (en) 2015-12-11
CO7061067A2 (es) 2014-09-19
IL231809B (en) 2019-06-30
IL231809A0 (en) 2014-05-28
SG10201600410SA (en) 2016-02-26
US20130085167A1 (en) 2013-04-04
EP2766017B1 (en) 2020-07-01
JP6134722B2 (ja) 2017-05-24
SG11201401248YA (en) 2014-05-29
HK1201204A1 (en) 2015-08-28

Similar Documents

Publication Publication Date Title
ES2973279T3 (es) Usos de medicamento de duloxetina·HCl en la preparación de una composición farmacéutica para el tratamiento de cáncer
CL2013002612A1 (es) Compuestos derivados de c4-monometil triterpenoides; composicion farmaceutica que los comprende; y metodo para tratar o prevenir una enfermedad o un trastorno.
DK2709667T3 (da) Bio-orthogonal lægemiddelaktivering
BR112013033803A2 (pt) formulação integrada com microagulha, e, método para administrar uma substância
ECSP14013329A (es) Compuestos de arylcarbonil-4-oxy-piperidina utilizados para el tratamiento de enfermedades neurodegenerativas
DK3750545T3 (da) Phospholipidetheranaloger som cancermålrettede lægemiddelbærere
BR112017009342A2 (pt) formulações e tratamentos para cuidado com a pele
CO7061081A2 (es) Derivados macrocíclicos para el tratamiento de enfermedades
CL2014002342A1 (es) Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma.
BR112013028273A2 (pt) método para estimular um procedimento médico e artigo
CL2015000744A1 (es) Combinación de regorafenib y ácido acetilsalicílico para el tratamiento del cáncer.
CO6820281A1 (es) Cepillo de dientes que proporciona retroalimentación prácticamente instantanea
UY33863A (es) Metodos y medicamentos para el tratamiento de la enfermedad de alzheimer
BR112015001899A2 (pt) interface de paciente e método para produzir a mesma.
UY34165A (es) ?compuestos aldh-2 mitocondriales humanos para el tratamiento de la adicción?.
BR112014026570A2 (pt) microagulha, arranjo e dispositivo de microagulha, e, método para administração de uma droga
BR112013014546A2 (pt) dispositivo e método para administração de um dispositivo vascular
BR112013029507A2 (pt) método para tratar uma doença ou um distúrbio
CL2014000799A1 (es) Un metodo para el tratamiento de un paciente que ha sufrido un accidente cerebrovascular que comprende administrar aminopiridina o una de sus sales
BR112013024934A2 (pt) aparelho de geração de 1-metilciclopropeno
DK3229873T3 (da) Drivmekanisme til anvendelse i en lægemiddelleveringsanordning
CO6821965A2 (es) 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia
BR112014029487A2 (pt) método para o tratamento cosmético
MA43100A (fr) Nanoparticules à utiliser en tant que vaccin thérapeutique
BR112014000217A2 (pt) formulação e método para a criação de uma formulação que estabiliza a proteína terapêutica